Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Precision BioSciences
(NASDAQ:DTIL)
Intraday
$10.23
0.41
[4.18%]
After-Hours
$10.23
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$10.23
0.41
[4.18%]
At close: Apr 24
$10.23
0
[0.00%]
PreMarket: 9:27AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Precision BioSciences Stock (NASDAQ:DTIL)
Precision BioSciences Stock (NASDAQ: DTIL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Benzinga Newsdesk
-
Apr 17, 2024, 1:26PM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Apr 17, 2024, 8:08AM
Tuesday, April 16, 2024
Precision BioSciences Announces Return Of Programs And Conclusion Of Collaboration With Prevail Therapeutics
Benzinga Newsdesk
-
Apr 16, 2024, 4:17PM
Thursday, April 04, 2024
iECURE Announces FDA Clearance Of IND Application For ECUR-506 To Initiate OTC-HOPE Trial For Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency In The U.S.; NOTE: iECURE Has Licensed The ARCUS Nuclease For ECUR-506 From Precision BioSciences
Benzinga Newsdesk
-
Apr 4, 2024, 11:02AM
Thursday, March 28, 2024
HC Wainwright & Co. Maintains Buy on Precision BioSciences, Adjusts Price Target To $60
Benzinga Newsdesk
-
Mar 28, 2024, 10:56AM
Wednesday, March 27, 2024
Precision Biosciences' 2023 Cash And Cash Equivalents Of $116.7M, Cash Received From TG Therapeutics, Caribou Of $50M, And $40M Capital Raise Is Expected To Provide Cash Runway Into 2H Of 2026
Benzinga Newsdesk
-
Mar 27, 2024, 6:58AM
Precision BioSciences Q4 GAAP EPS $(4.06) May Not Be Comparable To $(2.05) Estimate, Sales $7.04M Miss $12.48M Estimate
Benzinga Newsdesk
-
Mar 27, 2024, 6:48AM
Earnings Scheduled For March 27, 2024
Benzinga Insights
-
Mar 27, 2024, 5:02AM
Tuesday, March 26, 2024
Earnings Preview: Precision BioSciences
Benzinga Insights
-
Mar 26, 2024, 1:00PM
Wednesday, March 06, 2024
Precision BioSciences Announces MHRA Approval For Partner iECURE To Expand Phase 1/2 Clinical Trial Of ARCUS Gene Editing Program In OTC Deficiency
Benzinga Newsdesk
-
Mar 6, 2024, 8:45AM
Friday, March 01, 2024
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Mar 1, 2024, 1:19PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Mar 1, 2024, 12:34PM
Precision BioSciences shares are trading lower after the company announced a $40 million offering of common stock and warrants.
Benzinga Newsdesk
-
Mar 1, 2024, 10:55AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Mar 1, 2024, 8:09AM
Precision BioSciences Discloses $40M Offering of Common Stock And Warrants, Warrants Have An Exercise Price Of $20.00 Per Share And Are Exercisable Immediately
Benzinga Newsdesk
-
Mar 1, 2024, 6:40AM
Thursday, February 29, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Feb 29, 2024, 4:31PM
Precision BioSciences Announces Proposed Public Offering Of Common Stock And Warrants; Terms Not Disclosed
Benzinga Newsdesk
-
Feb 29, 2024, 4:04PM
Tuesday, February 27, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Feb 27, 2024, 8:06AM
Tuesday, February 20, 2024
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences, Financial Terms Undisclosed
Benzinga Newsdesk
-
Feb 20, 2024, 7:08AM
Wednesday, February 14, 2024
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $3 Price Target
Benzinga Newsdesk
-
Feb 14, 2024, 1:42PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk
-
Feb 14, 2024, 8:55AM
Precision BioSciences Receives Pre-IND Feedback From FDA For PBGENE-HBV As It Advances Towards Clinical Readiness
Benzinga Newsdesk
-
Feb 14, 2024, 7:15AM
Tuesday, February 13, 2024
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
-
Feb 13, 2024, 7:50PM
Monday, February 12, 2024
Precision Biosciences Received An Initial $7.5M Upfront Cash Payment And Equity Investment From TG Therapeutics For An Exclusive License To Develop Azercabtagene Zapreleucel For Autoimmune Diseases And Other Indications Outside Of Cancer
Benzinga Newsdesk
-
Feb 12, 2024, 7:07AM
Friday, February 09, 2024
Precision BioSciences Plans To Effect 1-For-30 Reverse Stock Split
Benzinga Newsdesk
-
Feb 9, 2024, 7:02AM
Tuesday, January 30, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Jan 30, 2024, 8:05AM
Wednesday, January 10, 2024
Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?
Lekha Gupta
-
Jan 10, 2024, 8:48AM
Tuesday, January 09, 2024
Precision BioSciences shares are trading higher after the company announced it completed a license deal with TG Therapeutics to develop Azer-Cel for autoimmune diseases.
Benzinga Newsdesk
-
Jan 9, 2024, 12:01PM
Why Precision BioSciences Stock Is Up Today
Erica Kollmann
-
Jan 9, 2024, 11:39AM
Precision BioSciences Strikes $17.5M Gene Editing Deal with TG Therapeutics, Eyeing $288M in Future Milestones
Benzinga Newsdesk
-
Jan 9, 2024, 7:05AM
Wednesday, December 13, 2023
Precision Biosciences Announced That Its Partner iECURE Received Approval From The Australian Therapeutic Goods Administration For The Initiation Of A First-In-Human Phase 1/2 Trial Evaluating ECUR-506
Benzinga Newsdesk
-
Dec 13, 2023, 8:22AM
Tuesday, December 05, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Dec 5, 2023, 8:07AM
Monday, December 04, 2023
Precision Biosciences Announced Publication In The Journal Nature Metabolism That Includes Preclinical Research Supporting Continued Development Of The PBGENE-PMM In Vivo Gene Editing Program For M.3243-associated Primary Mitochondrial Myopathy
Benzinga Newsdesk
-
Dec 4, 2023, 7:01AM
Tuesday, November 07, 2023
Precision BioSciences' Q3 Cash Balance Of $122.2M, Expected To Provide Extended Cash Runway Through The End Of 2025
Benzinga Newsdesk
-
Nov 7, 2023, 7:19AM
Precision BioSciences Q3 EPS $(0.07) Beats $(0.17) Estimate, Sales $13.12M Beat $8.60M Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 7:18AM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Monday, November 06, 2023
Earnings Outlook For Precision BioSciences
Benzinga Insights
-
Nov 6, 2023, 4:01PM
Wednesday, November 01, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Nov 1, 2023, 1:31PM
Thursday, October 26, 2023
Precision BioSciences Presents Preclinical Data Highlighting Capabilities Of ARCUS For Gene Insertion And Excision At The European Society Of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Benzinga Newsdesk
-
Oct 26, 2023, 7:40AM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Wednesday, September 27, 2023
Precision Biosciences Has Received A Notice Of Allowance From The U.S. Patent And Trademark Office Related To Engineered Meganucleases That Target Human Mitochondrial Genomes, Once Issued, The Patent Expiry Stands At April 2024
Benzinga Newsdesk
-
Sep 27, 2023, 7:10AM
Tuesday, September 26, 2023
Why Femasys Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Sep 26, 2023, 8:05AM
Tuesday, September 19, 2023
What 4 Analyst Ratings Have To Say About Precision BioSciences
Benzinga Insights
-
Sep 19, 2023, 2:00PM
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $3 Price Target
Benzinga Newsdesk
-
Sep 19, 2023, 12:02PM
Tuesday, September 12, 2023
Precision Biosciences Hosts Virtual R&D Day Highlighting Its Arcus Technology And Recent In Vivo Gene Editing Program Developments
Benzinga Newsdesk
-
Sep 12, 2023, 7:16AM
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 8, 2023, 1:58PM
Thursday, August 17, 2023
What Is Precision BioSciences CAR T Pipeline Value? Analyst Lowers Price Target To Justify Valuation
Vandana Singh
-
Aug 17, 2023, 2:18PM
Precision BioSciences shares are trading lower after HC Wainwright maintained a Buy rating on the stock but lowered its price target from $5 to $3.
Benzinga Newsdesk
-
Aug 17, 2023, 11:06AM
The Latest Analyst Ratings for Precision BioSciences
Benzinga Insights
-
Aug 17, 2023, 9:00AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch